ISRCTN12590498
Completed
未知
A randomised, double-blind, placebo-controlled study on the impact of Lorazepam on approach/avoidance behaviour in healthy individuals
Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)0 sites60 target enrollmentDecember 8, 2014
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
- 2017 results in https://www.ncbi.nlm.nih.gov/pubmed/28364943 (added 23/01/2019)
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Informed Consent as documented by signature
- •2\. Age 18 – 40 years
Exclusion Criteria
- •1\. Contraindications to benzodiazepines: dependence or former dependence, history of allergic reactions, history of hypotonia associated with benzodiazepines
- •2\. Use of any drugs in the 2 weeks prior to the study with the exception of contraceptive drugs and incidental use of NSARs or paracetamol
- •3\. Women who are pregnant or breast feeding
- •4\. Intention to become pregnant during the course of the study
- •5\. Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases
- •6\. Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)
- •7\. Any history of psychiatric, neurological, dependence or systemic/rheumatic disease
- •8\. Known or suspected non\-compliance, drug or alcohol abuse
- •9\. Inability to follow the procedures of the study, e.g. due to language problems
- •10\. Participation in another study with investigational drug within the 30 days preceding and during the present study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Study to evaluate the safety and efficacy of CCX168 in subjects with renal vasculitis on background cyclophosphamide treatmentRenal VasculitisCirculatory SystemRenal vasculitisISRCTN53663626ChemoCentryx, Inc. (USA)60
Completed
Not Applicable
A trial of Exenatide for the treatment of moderate severity Parkinson's diseaseTopic: Dementias and Neurodegenerative Diseases Research NetworkSubtopic: Parkinson?s DiseaseDisease: Parkinson's diseaseNervous System DiseasesParkinson diseaseISRCTN75891427niversity College London (UK)60
Completed
Phase 1
A dose-escalating clinical trial with KH176ISRCTN43372293Khondrion30
Completed
Phase 2
Innovations in the management of musculoskeletal pain with alpha-lipoic acidISRCTN58259979Physicians Services Incorporated Foundation27
Completed
Phase 2
Cisplatin Ototoxicity attenuated by ASpirin Trial (COAST)CancerISRCTN83689269Southampton University Hospitals NHS Trust (UK)88